Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.
In: BMJ: British Medical Journal, Jg. 383 (2023-11-04), Heft 8405, S. 1-10
academicJournal
Zugriff:
Titel: |
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.
|
---|---|
Autor/in / Beteiligte Person: | Ma, Fei ; Yan, Min ; Li, Wei ; Ouyang, Quchang ; Tong, Zhongsheng ; Teng, Yuee ; Wang, Yongsheng ; Wang, Shusen ; Geng, Cuizhi ; Luo, Ting ; Zhong, Jincai ; Zhang, Qingyuan ; Liu, Qiang ; Zeng, Xiaohua ; Sun, Tao ; Mo, Qinguo ; Liu, Hu ; Cheng, Ying ; Cheng, Jing ; Wang, Xiaojia |
Zeitschrift: | BMJ: British Medical Journal, Jg. 383 (2023-11-04), Heft 8405, S. 1-10 |
Veröffentlichung: | 2023 |
Medientyp: | academicJournal |
ISSN: | 1756-1833 (print) |
DOI: | 10.1136/bmj-2023-076065 |
Schlagwort: |
|
Sonstiges: |
|